Provided by Tiger Trade Technology Pte. Ltd.

Quantum Biopharma Ltd.

3.68
+0.03000.82%
Volume:168.35K
Turnover:638.21K
Market Cap:29.76M
PE:-0.69
High:3.88
Open:3.63
Low:3.63
Close:3.65
52wk High:21.00
52wk Low:2.07
Shares:8.09M
Float Shares:7.65M
Volume Ratio:1.03
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3537
EPS(LYR):-7.9660
ROE:-621.46%
ROA:-51.84%
PB:3.74
PE(LYR):-0.46

Loading ...

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 PM

Reuters
·
Jun 02

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study

TIPRANKS
·
May 19

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

GlobeNewswire
·
May 18

Press Release: Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Dow Jones
·
May 07

Quantum BioPharma Provides Corporate Update

GlobeNewswire
·
Apr 28

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

GlobeNewswire
·
Apr 22

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

GlobeNewswire
·
Apr 02

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

GlobeNewswire
·
Apr 01

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM

Reuters
·
Mar 30

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

GlobeNewswire
·
Mar 30

Quantum Biopharma Provides Corporate Update

GlobeNewswire
·
Mar 28

Press Release: Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status

Dow Jones
·
Mar 27

Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate

Benzinga Earnings
·
Mar 27

Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

GlobeNewswire
·
Mar 26

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

GlobeNewswire
·
Mar 23